Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZyVersa Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 6.0% of the aggregate gross proceeds and reimbursement of $100,000 of expenses (effective 2023-07-24).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- A.G.P./Alliance Global Partners
- Value
- 6.0% of the aggregate gross proceeds and reimbursement of $100,000 of expenses
- Effective
- 2023-07-24
Exact text from the filing
A.G.P./Alliance Global Partners (“A.G.P.”) acted as the sole placement agent for the Offering and received a fee of 6.0% of the aggregate gross proceeds and reimbursement of $100,000 of expenses, pursuant to a placement agency agreement between the Company and A.G.P. (the “Placement Agency Agreement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZyVersa Therapeutics, Inc. amended Warrant Amendment (effective 2023-07-24).
- Action
- amendment
- Effective
- 2023-07-24
Exact text from the filing
the Company amended (such amendment, the “Warrant Amendment”) certain existing warrants to purchase 1,377,996 shares of common stock that were issued in a completed best efforts offering in April 2023 (the “Best Efforts Warrants”) to reduce the existing $1.00 exercise price of the Best Efforts Warrants to the exercise price of the warrants being offered and sold in this Offering and to extend the current April 28, 2028 expiration date of the Best Efforts Warrants to the expiration date of the warrants being offered and sold in this Offering.
View on SEC.gov